Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-01-26

Clinical Trial Update: Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing carboplatin with or without nivolumab in metastatic triple-negative breast cancer. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CARBOPLATIN (Carboplatin)
  • nivolumab (nivolumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-01-26